よむ、つかう、まなぶ。
10参考資料１ 新型コロナワクチンに関する資料 (80 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000192554_00027.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会（第52回 2／8）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
https://doi.org:10.1056/NEJMoa2203209
39
Chemaitelly, H. et al. Covid-19 Vaccine Protection among Children and Adolescents in
Qatar. N Engl J Med 387, 1865-1876 (2022). https://doi.org:10.1056/NEJMoa2210058
40
Jang, E. J., Choe, Y. J., Kim, R. K. & Park, Y. J. BNT162b2 Vaccine Effectiveness Against
the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years. JAMA Pediatr (2023).
https://doi.org:10.1001/jamapediatrics.2022.5221
41
Hause, A. M. et al. Safety of COVID-19 Vaccination in United States Children Ages 5 to
11 Years. Pediatrics 150 (2022). https://doi.org:10.1542/peds.2022-057313
42
独立行政法人医薬品医療危機総合機構. 特例承認に係る報告書（コミナティ筋注 5～11
歳
用
_
フ
ァ
イ
ザ
ー
株
式
会
社
）
,
<https://www.pmda.go.jp/drugs/2022/P20220826003/672212000_30400AMX00015_
A100_1.pdf> (2022).
43
Khan, F. L. et al. Estimated BNT162b2 Vaccine Effectiveness Against Infection With
Delta and Omicron Variants Among US Children 5 to 11 Years of Age. JAMA Netw Open
5, e2246915 (2022). https://doi.org:10.1001/jamanetworkopen.2022.46915
44
Hause, A. M. et al. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster
Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022. MMWR
Morb
Mortal
Wkly
Rep
71,
1047-1051
(2022).
https://doi.org:10.15585/mmwr.mm7133a3
45
Gruber, W. C. BNT162b2 (COVID-19 vaccine, mRNA) 6 months through 4 years of age,
<https://stacks.cdc.gov/view/cdc/118383> (2022).
46
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy
in Children 6 Months through 4 Years of Age https://www.pfizer.com/news/pressrelease/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccinedata,
<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-
biontech-announce-updated-covid-19-vaccine-data> (
47
独立行政法人医薬品医療危機総合機構. 特例承認に係る報告書（コミナティ筋注 6 ヵ月
～
4
歳
用
_
フ
ァ
イ
ザ
ー
株
式
会
社
）
,
<https://www.pmda.go.jp/drugs/2022/P20220926003/672212000_30400AMX00438_
A100_2.pdf> (2022).
48
コミナティ筋注 6 ヵ月～4 歳用ファイザー株式会社 特例承認に係る報告書
49
Hause, A. M. et al. COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5
Years - United States, June 18, 2022-August 21, 2022. MMWR Morb Mortal Wkly Rep
71, 1115-1120 (2022). https://doi.org:10.15585/mmwr.mm7135a3
50
Toepfner, N. et al. Comparative Safety of the BNT162b2 Messenger RNA COVID-19
Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. JAMA Netw
80
39
Chemaitelly, H. et al. Covid-19 Vaccine Protection among Children and Adolescents in
Qatar. N Engl J Med 387, 1865-1876 (2022). https://doi.org:10.1056/NEJMoa2210058
40
Jang, E. J., Choe, Y. J., Kim, R. K. & Park, Y. J. BNT162b2 Vaccine Effectiveness Against
the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years. JAMA Pediatr (2023).
https://doi.org:10.1001/jamapediatrics.2022.5221
41
Hause, A. M. et al. Safety of COVID-19 Vaccination in United States Children Ages 5 to
11 Years. Pediatrics 150 (2022). https://doi.org:10.1542/peds.2022-057313
42
独立行政法人医薬品医療危機総合機構. 特例承認に係る報告書（コミナティ筋注 5～11
歳
用
_
フ
ァ
イ
ザ
ー
株
式
会
社
）
,
<https://www.pmda.go.jp/drugs/2022/P20220826003/672212000_30400AMX00015_
A100_1.pdf> (2022).
43
Khan, F. L. et al. Estimated BNT162b2 Vaccine Effectiveness Against Infection With
Delta and Omicron Variants Among US Children 5 to 11 Years of Age. JAMA Netw Open
5, e2246915 (2022). https://doi.org:10.1001/jamanetworkopen.2022.46915
44
Hause, A. M. et al. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster
Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022. MMWR
Morb
Mortal
Wkly
Rep
71,
1047-1051
(2022).
https://doi.org:10.15585/mmwr.mm7133a3
45
Gruber, W. C. BNT162b2 (COVID-19 vaccine, mRNA) 6 months through 4 years of age,
<https://stacks.cdc.gov/view/cdc/118383> (2022).
46
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy
in Children 6 Months through 4 Years of Age https://www.pfizer.com/news/pressrelease/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccinedata,
<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-
biontech-announce-updated-covid-19-vaccine-data> (
47
独立行政法人医薬品医療危機総合機構. 特例承認に係る報告書（コミナティ筋注 6 ヵ月
～
4
歳
用
_
フ
ァ
イ
ザ
ー
株
式
会
社
）
,
<https://www.pmda.go.jp/drugs/2022/P20220926003/672212000_30400AMX00438_
A100_2.pdf> (2022).
48
コミナティ筋注 6 ヵ月～4 歳用ファイザー株式会社 特例承認に係る報告書
49
Hause, A. M. et al. COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5
Years - United States, June 18, 2022-August 21, 2022. MMWR Morb Mortal Wkly Rep
71, 1115-1120 (2022). https://doi.org:10.15585/mmwr.mm7135a3
50
Toepfner, N. et al. Comparative Safety of the BNT162b2 Messenger RNA COVID-19
Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. JAMA Netw
80